Back to Treatments

Treatment

Dasatinib (for Ph+ ALL)

1
Conditions
35
Trials
10K
Participants
55%
Average Safety

Condition Evidence

Acute lymphoid leukemia

35 trials · 10K participants

88% effectiveness · 55% safety
Dasatinib (for Ph+ ALL) | DFDA